Cargando…

DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features

Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage. DNA methylation is an important DNA modification that regulates gene expression. Investigating AML heterogeneity based on DNA methylation could be clinically informative for improving clinical diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Jian, Jimo, Yuan, Chenglu, Ji, Chunyan, Hao, Hongyuan, Lu, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543573/
https://www.ncbi.nlm.nih.gov/pubmed/36645547
http://dx.doi.org/10.1007/s10238-022-00980-4
_version_ 1785114319593144320
author Jian, Jimo
Yuan, Chenglu
Ji, Chunyan
Hao, Hongyuan
Lu, Fei
author_facet Jian, Jimo
Yuan, Chenglu
Ji, Chunyan
Hao, Hongyuan
Lu, Fei
author_sort Jian, Jimo
collection PubMed
description Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage. DNA methylation is an important DNA modification that regulates gene expression. Investigating AML heterogeneity based on DNA methylation could be clinically informative for improving clinical diagnosis and prognosis. The AML subtypes based on DNA methylation were identified by unsupervised consensus clustering. The association of these subtypes with gene mutation, copy number variations, immune infiltration and clinical features were further explored. Finally, univariate, LASSO and multivariate cox regression analyses were used to identify prognosis-associated genes and construct risk model for AML patients. In addition, we validated this model by using other datasets and explored the involved biological functions and pathways of its related genes. Three CpG island methylator phenotypes (CIMP-H, CIMP-M and CIMP-L) were identified using the 91 differential CpG sites. Overall survival, morphology, macrophages M0 and monocytes were distinct from each other. The most frequently mutated gene in CIMP-L was DNMT3A while which in CIMP-M that was RUNX1. In addition, the TIDE scores, used to predict the response to immune checkpoint inhibitors, were significantly different among CIMPs. The CIMP-associated prognosis risk model (CPM) using 32 key genes had convinced accuracy of prediction to forecast 0.5-year, 1-year, 3-year and 5-year survival rates. Moreover, the risk score-related genes were significantly enriched in pattern specification process, regionalization, embryonic organ morphogenesis and other critical cancer-related biological functions. We systematically and comprehensively analyzed the DNA methylation in AML. The risk model we constructed is an independent predictor of overall survival in AML and could be used as prognostic factor for AML treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10238-022-00980-4.
format Online
Article
Text
id pubmed-10543573
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-105435732023-10-03 DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features Jian, Jimo Yuan, Chenglu Ji, Chunyan Hao, Hongyuan Lu, Fei Clin Exp Med Research Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage. DNA methylation is an important DNA modification that regulates gene expression. Investigating AML heterogeneity based on DNA methylation could be clinically informative for improving clinical diagnosis and prognosis. The AML subtypes based on DNA methylation were identified by unsupervised consensus clustering. The association of these subtypes with gene mutation, copy number variations, immune infiltration and clinical features were further explored. Finally, univariate, LASSO and multivariate cox regression analyses were used to identify prognosis-associated genes and construct risk model for AML patients. In addition, we validated this model by using other datasets and explored the involved biological functions and pathways of its related genes. Three CpG island methylator phenotypes (CIMP-H, CIMP-M and CIMP-L) were identified using the 91 differential CpG sites. Overall survival, morphology, macrophages M0 and monocytes were distinct from each other. The most frequently mutated gene in CIMP-L was DNMT3A while which in CIMP-M that was RUNX1. In addition, the TIDE scores, used to predict the response to immune checkpoint inhibitors, were significantly different among CIMPs. The CIMP-associated prognosis risk model (CPM) using 32 key genes had convinced accuracy of prediction to forecast 0.5-year, 1-year, 3-year and 5-year survival rates. Moreover, the risk score-related genes were significantly enriched in pattern specification process, regionalization, embryonic organ morphogenesis and other critical cancer-related biological functions. We systematically and comprehensively analyzed the DNA methylation in AML. The risk model we constructed is an independent predictor of overall survival in AML and could be used as prognostic factor for AML treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10238-022-00980-4. Springer International Publishing 2023-01-16 2023 /pmc/articles/PMC10543573/ /pubmed/36645547 http://dx.doi.org/10.1007/s10238-022-00980-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Jian, Jimo
Yuan, Chenglu
Ji, Chunyan
Hao, Hongyuan
Lu, Fei
DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features
title DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features
title_full DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features
title_fullStr DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features
title_full_unstemmed DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features
title_short DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features
title_sort dna methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543573/
https://www.ncbi.nlm.nih.gov/pubmed/36645547
http://dx.doi.org/10.1007/s10238-022-00980-4
work_keys_str_mv AT jianjimo dnamethylationbasedsubtypesofacutemyeloidleukemiawithdistinctprognosisandclinicalfeatures
AT yuanchenglu dnamethylationbasedsubtypesofacutemyeloidleukemiawithdistinctprognosisandclinicalfeatures
AT jichunyan dnamethylationbasedsubtypesofacutemyeloidleukemiawithdistinctprognosisandclinicalfeatures
AT haohongyuan dnamethylationbasedsubtypesofacutemyeloidleukemiawithdistinctprognosisandclinicalfeatures
AT lufei dnamethylationbasedsubtypesofacutemyeloidleukemiawithdistinctprognosisandclinicalfeatures